The Covid-19 vaccine rollout has given drugmakers the kind of brand-name shorthand usually reserved for more mundane consumer products: People talk about getting Pfizer, Moderna, J&J, or Astra much as they might reach for a Kleenex or a Popsicle. And those companies have contracts to provide billions of doses, appearing to leave little room for other entrants. So why are dozens of hopefuls still working on shots?
The answer is that while early leaders stand to book immense profits, the problem is big enough—and the continuing challenges daunting enough—to leave room for at least a few more companies. The offerings of two that got to the market quickly, AstraZeneca Plc and Johnson & Johnson, have been linked to rare blood clots, slowing their rollout. The handling requirements and high cost of the Moderna and Pfizer-BioNTech messenger RNA vaccines mean governments in poorer places would welcome a cheaper, easier-to-ship alternative. And the rise of new variants opens the door to shots that target the evolving coronavirus. “While we’re thrilled with the vaccines that we have, and we’re so lucky that these vaccines turned out to have such high efficacy and a good safety profile, we can improve further,” says Soumya Swaminathan, the World Health Organization’s chief scientist.
Continue reading your story on the app
Continue reading your story in the magazine
When Employees Go, Data Can Leave, Too
Cybersecurity professionals fear that job cuts can lead to vulnerabilities
The Word That Went Unsaid at Davos
The outlook among global leaders at the World Economic Forum in Davos, Switzerland, in mid-January ranged from cautiously optimistic to unapologetically positive. Attendees interviewed by Bloomberg News during the proceedings talked about the reopening of China, the warmer-than-expected winter, which has helped keep energy prices down, and the expected surge in other commodity prices that hasn't occurred.
Mercedes makes the G-Wagen bigger, badder and in a way I didn't think possible better.
A Natural Touch For Jewelry
Collectors clamor for Emmanuel Tarpin’s one-of-a-kind pieces.
These Watches Are Not for You
Max Büsser and his band of revolutionaries made products they themselves wanted-and built a huge fandom on the way.
Small watchmakers are soaring thanks to a boom in timepiece: collecting and a supply crunch among the most famous Swiss brands.
Middle-aged tech centimillionaire Bryan Johnson and his team of 30 doctors say they have a plan to reboot his body
Big Brother at Bargain
NSO Group and its rivals have made military-grade surveillance software shockingly affordable. The way it was used against the real-life hero of Hotel Rwanda might finally force lawmakers' hands
Trolling While on Autopilot
Amid falling demand and sudden price cuts, Elon Musk seems determined to take a blowtorch to his car company’s brand
Tackling Textile Waste
A machine that sorts unwearable clothing is helping divert items away from landfill
5 Facts About the New Covid Booster
What you need to know to further protect yourself & your loved ones
China's Bet On Homegrown mRNA Vaccines Holds Back Nation
China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19.
Time for a Boost
As changes to the vaccine policy are announced we unpack what you need to know
MOST EFFECTIVE COVID VACCINES
CDC says mRNA works – China’s jabs are JUNK!
MIRACLE COVID DRUG COMES WITH A CATCH!
A BREAKTHROUGH medication has been approved by the FDA to fight COVID-19, but it can cause potentially life-threatening interactions with a variety of widely prescribed drugs, warned experts.
Vacuna COVID-19 en niños: soluciona tus dudas
Los pequeños de 5 a 11 años ya pueden vacunarse frente al coronavirus. De la mano de dos expertos en Pediatría, resolvemos algunas cuestiones que preocupan a los padres.
Dig Into Analysts' Estimates for Disruptive Companies
THE PANDEMIC ERA generated a whole wave of disruptive companies as it accelerated the introduction of new products and services in areas including artificial intelligence, digitization, electronic payments, online meeting platforms, and virtual currencies.
The World's 50 Most Innovative Companies – Biotech
Mariana Matus Cofounder and CEO of Biobot Analytics
More uses for new mRNA technology
The Last Pandemic
Technological breakthroughs and policy progress mean humanity may never again have to endure a disaster like Covid-19.